Pamela Randolph Jackson, MD
Radiation Oncology · Washington, DCNPI 1801813407
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,260 of the $1,612 with a category attached, or 78.2%. AstraZeneca accounts for 78.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $1,312 and has fallen 93.9% since, to $81 in 2025.
Across 15 payments — averaging $107.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Tactile Systems Technology Inc$132
- Sumitomo Pharma America, Inc.$78
- Merck$67
- Boston Scientific$52
- Elekta, Inc.$23
What the payments were for
- Consulting fees$1,26078%
- Food & beverage$33121%
- Education$211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $1,260 |
| Tactile Systems Technology Inc | 8 | $132 |
| Sumitomo Pharma America, Inc. | 1 | $78 |
| Merck | 2 | $67 |
| Boston Scientific | 2 | $52 |
| Elekta, Inc. | 1 | $23 |
How this compares
$1,612 in reported general payments places this provider in the 55th percentile of 25 radiation oncology providers in District of Columbia.
See all radiation oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 15 | $40,155 |
| Tamsulosin Hcl | 47 | $409 |
| Dexamethasone | 12 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $78 | $40,15515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 25 radiation oncology providers in District of Columbia.
Other radiation oncology in Washington
- Sean CollinsWashington$395K
- Jonathan LischalkWashington$55K
- Christina TsienWashington$53K
- Brian CollinsWashington$27K
- Keith UngerWashington$5K
- Rajanish SinglaWashington$5K
- Rachit KumarWashington$4K
- Martin Ojong-NtuiWashington$2K
- Jill RemickWashington$2K
- Matthew ForsthoefelWashington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.